Tech Transfer Monetization
Traditional tech transfer often optimizes for process and internal constraints. MIM focuses on portfolio outcomes. That means identifying what is commercially real, stopping spend on assets that will never move, packaging the right assets into deal-ready forms, and creating a repeatable path from invention to credible transaction.
This is not simply tech transfer support. It is a portfolio-management approach to institutional commercialization: triage, invest where the market exists, build clear deal positions, and move assets through a more disciplined commercialization funnel while preserving institutional guardrails.
Who This Is For
University or institute leadership seeking stronger commercialization outcomes with limited budgets.
General counsel or tech-transfer leaders who need a governable process and less leakage.
Foundations, affiliated entities, or investors who need clarity on what is commercializable.
Commercialization teams that need packaging and targeting that resonates with licensees.
Common Starting Triggers
We are spending money maintaining assets that will never license.
Licensing throughput is low and unpredictable.
Our portfolio narrative is not credible to industry.
Negotiations take too long and outcomes are uneven.
We need a more commercial, portfolio-first system.
Outcomes You Can Expect
A clearer view of what to invest in and what to stop funding.
A repeatable triage rubric and segmentation model.
Faster movement from interesting science to deal-ready assets.
A more practical licensee funnel and outreach strategy.
Standardized deal positions that reduce negotiation friction and protect upside.
Case Snapshots
Triage reset: segmented a broad portfolio into commercialize, invest, hold, and abandon, and redirected spend to high-leverage assets.
Packaging that sells: created consistent deal briefs and claim-coverage narratives that reduced friction with potential licensees.
Standardized position: implemented repeatable deal positions that shortened negotiation cycles and protected institutional upside.